Understanding the Current Paradigm and New Approaches in the Care of Patients with Pancreatic Cancer

Accreditation types: 1.75 NCPD

Expired: May 2026

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Farshid Dayyani

Faculty

Farshid Dayyani

MD, PhD

University of California, Irvine, Orange, California

Professor of Clinical Medicine, Medical Director, Stern Center for Cancer Clinical Trials and Research, Associate Director for Translational Science, UCI Chao Family Comprehensive Cancer Center

Caroline Kuhlman

Faculty

Caroline Kuhlman

MSN, APRN-BC

Massachusetts General Brigham Cancer Institute, Boston, Massachusetts

Nurse Practitioner, Tucker Gosnell Center for Gastrointestinal Cancers

Philip A Philip

Faculty

Philip A Philip

MD, PhD

Wayne State University Department of Oncology, Detroit, Michigan

Chair, Hematology and Oncology, Professor of Oncology and Pharmacology, Co-Leader, Pancreatic Cancer Program, Medical Director, Cancer Clinical and Translational Research Office, Chair, GI Cancer, SWOG, Henry Ford Cancer Institute

Amanda K Wagner

Faculty

Amanda K Wagner

APRN-CNP, AOCNP

The James Cancer Hospital, The Ohio State University, Columbus, Ohio

GI Malignancies

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.

LEARNING OBJECTIVES

  • Appreciate the biological, clinical and logistical factors that affect the selection of first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma (PAD), and incorporate this information into patient education discussions.
  • Assess published efficacy findings with regimens incorporating novel chemotherapeutic formulations as first-line therapy for patients with metastatic PAD, and understand the current role of these approaches.
  • Recognize FDA-approved and commonly employed treatment approaches for metastatic PAD that has progressed on front-line chemotherapy, and counsel patients regarding the risks and benefits of these agents and regimens.
  • Appraise available Phase III data with PARP inhibitor maintenance after first-line platinum-based chemotherapy for patients with newly diagnosed PAD and a germline BRCA mutation, and consider the diagnostic and therapeutic implications of these findings.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed in the management of PAD, to support quality of life and continuation of therapy.
  • Recall the biological rationale for and available and emerging data with investigational approaches currently in clinical testing for PAD, and appropriately refer patients for trial participation.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
NCPD credit is no longer available for this issue.

ONCC/ILNA CERTIFICATION INFORMATION
NCPD credit is no longer available for this issue.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
NCPD credit is no longer available for this issue.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Farshid Dayyani, MD, PhD
Professor of Clinical Medicine
Medical Director, Stern Center for Cancer Clinical Trials and Research
Associate Director for Translational Science
UCI Chao Family Comprehensive Cancer Center
University of California, Irvine
Orange, California

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Jazz Pharmaceuticals Inc, Sirtex Medical Ltd, Taiho Oncology Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Exelixis Inc, Genentech, a member of the Roche Group, Natera Inc, Pfizer Inc, Taiho Oncology Inc; Speakers Bureaus: Astellas, Ipsen Biopharmaceuticals Inc, Sirtex Medical Ltd, Takeda Pharmaceuticals USA Inc.

Caroline Kuhlman, MSN, APRN-BC
Nurse Practitioner
Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital
Boston, Massachusetts

No relevant conflicts of interest to disclose.

Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Henry Ford Cancer Institute
Wayne State University
Detroit, Michigan

Advisory Committees: Agenus Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Gilead Sciences Inc, HUYA Bioscience International, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Pfizer Inc, Processa Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen, BioNTech SE, Moderna, Novocure Inc; Data and Safety Monitoring Boards/Committees: Cyclacel Pharmaceuticals Inc, Oncolytics Biotech Inc; Speakers Bureaus: Astellas, Incyte Corporation.

Amanda K Wagner, APRN-CNP, AOCNP
GI Malignancies
The James Cancer Hospital
The Ohio State University
Columbus, Ohio

No relevant conflicts of interest to disclose.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Ipsen Biopharmaceuticals Inc.

Release date: May 2025
Expiration date: May 2026

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Ms Wagner

Module 1: Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD

Park W et al. Pancreatic cancer: A review. JAMA 2021;326(9):851-62. Abstract

Stoffel EM et al. Pancreatic cancer: Changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 2023;164(5):752-65. Abstract

 

Module 4: Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Metastatic PAD

Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381(4):317-27. Abstract

 

Dr Dayyani

Module 1: Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD

Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25. Abstract

Conroy T et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. ASCO 2010;Abstract 4010.

Ohba A et al. Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial. ESMO 2023;Abstract 1616O.

Ozaka M et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer 2023;181:135-44. Abstract

Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703. Abstract

Wainburg ZA et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 2023;402(10409):1272-81. Abstract

 

Module 2: Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD

Go S-I et al. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). Eur J Cancer 2021;157:21-30. Abstract

Huh G et al. Gemcitabine plus nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: A multicenter, single-arm, open-label, phase 2 trial. Ther Adv Med Oncol 2021;13. Abstract

Neuzillet C et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012;18(33):4533-41. Abstract

Sezgin Y et al. Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Sci Rep 2025;15(1):11675. Abstract

Wang-Gillam A et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet 2016;387(10018):545-57. Abstract

Zaniboni A et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: A GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012;69(6):1641-5. Abstract

 

Ms Kuhlman

Module 1: Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD

Nichetti F et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: A systematic review and meta-analysis. JAMA Netw Open 2024;7(1). Abstract

Wainberg ZA et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 2023;402(10409):1272-81. Abstract

 

Module 3: Importance of Palliative Care for Advanced PAD

Temel JS et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363(8):733-42. Abstract

 

Dr Philip

Module 4: Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Metastatic PAD

Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381(4):317-27. Abstract

Kindler HL et al. Overall survival results from the POLO trial: A phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 2022;40(34):3929-39. Abstract

Kindler HL et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. ASCO 2019;Abstract LBA4.

 

Module 5: Promising Investigational Strategies for PAD

Bekaii-Saab TS et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol 2023;41(25):4097-106. Abstract

Garrido-Laguna I et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). Gastrointestinal Cancers Symposium 2025;Abstract 722.

Kim D-W et al. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol 2024;20(16):1057-67. Abstract

Philip PA et al. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res 2022;28(12):2704-14. Abstract

Schram AM et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med 2025;392(6):566-76. Abstract

Singhal A et al. Targeting KRAS in cancer. Nat Med 2024;30(4):969-83. Abstract

Strickler JH et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med 2023;388(1):33-43. Abstract

  • for-nurses

Understanding the Current Paradigm and New Approaches in the Care of Patients with Endometrial Cancer

Accreditation types: 2.25 NCPD

Expired: May 2026

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Kathryn M Lyle

Faculty

Kathryn M Lyle

MSN, WHNP-BC, AGNP-C

The University of Alabama at Birmingham, Birmingham, Alabama

Nurse Practitioner, Division of Gynecologic Oncology

Ritu Salani

Faculty

Ritu Salani

MD, MBA

David Geffen School of Medicine at UCLA, Los Angeles, California

Director, Division of Gynecologic Oncology, Professor, Department of Obstetrics and Gynecology

Jaclyn Shaver

Faculty

Jaclyn Shaver

MS, APRN, CNP, WHNP

OU Health, Oklahoma City, Oklahoma

Section of Gynecologic Oncology, Stephenson Cancer Center

Brian M Slomovitz

Faculty

Brian M Slomovitz

MD

Mount Sinai Medical Center, Miami, Florida

Professor, OB-GYN, Florida International University, Director, Gynecologic Oncology, Co-Chair, Cancer Research Committee

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with endometrial cancer.

LEARNING OBJECTIVES

  • Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment in the management of EC, and adapt current testing practices to optimally identify patients with corresponding genetic abnormalities.
  • Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
  • Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC, and consider the potential role of this novel strategy.
  • Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and counsel patients with metastatic EC about the risks and benefits of this approach.
  • Review published clinical research documenting the efficacy of HER2-targeted agents and regimens for HER2-overexpressing EC, and evaluate the role of various approaches in patient care.
  • Appreciate the side effects associated with various systemic therapies commonly used in the treatment of EC, and develop supportive management plans for patients.
  • Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
NCPD credit is no longer available for this issue.

ONCC/ILNA CERTIFICATION INFORMATION
NCPD credit is no longer available for this issue.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
NCPD credit is no longer available for this issue.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess financial relationships with faculty, planners and managers of NCPD activities. Financial relationships are identified and resolved through a financial relationship resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Kathryn M Lyle, MSN, WHNP-BC, AGNP-C
Nurse Practitioner
Division of Gynecologic Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

No relevant financial relationships to disclose.

Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Advisory Committees: Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, Karyopharm Therapeutics, Merck, Pfizer Inc; Nonrelevant Financial Relationships: Elsevier, UpToDate.

Jaclyn Shaver, MS, APRN, CNP, WHNP
Section of Gynecologic Oncology
Stephenson Cancer Center
OU Health
Oklahoma City, Oklahoma

No relevant financial relationships to disclose.

Brian M Slomovitz, MD
Professor, OB-GYN, Florida International University
Director, Gynecologic Oncology
Co-Chair, Cancer Research Committee
Mount Sinai Medical Center
Miami, Florida

Consulting Agreements: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Incyte Corporation, Merck, Novartis, Regeneron Pharmaceuticals Inc, Seagen Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from GSK.

Release date: May 2025
Expiration date: May 2026

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Salani

Module 1: First-Line Therapy for Advanced or Recurrent EC

Eskander R et al. Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial. SGO 2024;Abstract LBA.

Eskander RN et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 2023;388(23):2159-70. Abstract

Levine DA, The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013 2;497(7447):67-73. Abstract

Mirza MR et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 2023;388(23):2145-58. Abstract

Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2024;42(3):283-99. Abstract

Westin SN et al. Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial. ESMO 2023;Abstract LBA41.

 

Module 2: Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC

Lorusso D et al. Health-related quality of life in patients with advanced endometrial cancer treated with lenvatinib plus pembrolizumab or treatment of physician’s choice. Eur J Cancer 2023;186:172-84. Abstract

Makker V et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: Updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. J Clin Oncol 2023;41(16):2904-10. Abstract

Makker V et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437-48. Abstract

Makker V et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab.Oncologist 2021;26(9):e1599-608. Abstract

Marth C et al. First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial. J Clin Oncol 2025;43(9):1083-100. Abstract

Marth C et al. Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase 3 ENGOT-en9/LEAP-001 study. ESGO 2024;Abstract 88.

 

Ms Lyle

Module 1: First-Line Therapy for Advanced or Recurrent EC

Martins F et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16(9):563-80. Abstract

 

Dr Slomovitz

Module 3: Novel Investigational Strategies for Newly Diagnosed Advanced EC

Makker V et al. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol 2024;185:202-11. Abstract

Mirza M et al. Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. SGO 2024;Abstract LBA.

Mirza MR et al. Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial. ESMO Gynecological Cancers Congress 2024;Abstract 38MO.

O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015;60(4):547-60. Abstract

Slomovitz BM et al. Long-term follow up of selinexor maintenance in patients with TP53wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study. 2023 ASCO Monthly Plenary Series;Abstract 427956.

Vergote I et al. Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. J Clin Oncol 2023;41(35):5400-10. Abstract

Vikas P et al. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol 2020;10:570. Abstract

Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2024;42:283-99. Abstract

 

Module 4: Incidence and Management of HER2-Positive EC

Fu Z et al. Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduct Target Ther 2022;7(1):93. Abstract

Hasegawa K et al. Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): A multicenter, phase II clinical trial. ESMO 2021;Abstract 813P.

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Nishikawa T et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE trial. J Clin Oncol 2023;41(15):2789-99. Abstract

 

Ms Shaver

Module 3: Novel Investigational Strategies for Newly Diagnosed Advanced EC

Vergote I et al. ENGOT-EN20/GOG-3083/XPORT-EC-042 – a phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: Rationale, methods, and trial design. Int J Gynecol Cancer 2024;34(8):1283-9. Abstract

  • for-nurses

Understanding the Current Paradigm and New Approaches in the Care of Patients with Gastroesophageal Cancers

Accreditation types: 1.75 NCPD

Expired: May 2026

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Sunnie Kim

Faculty

Sunnie Kim

MD

University of Colorado Cancer Center, Aurora, Colorado

GI Medical Oncologist, Associate Professor

Brooke Parker

Faculty

Brooke Parker

MSN, FNP

UCHealth Cancer Care, Aurora, Colorado

Gastrointestinal Oncology Nurse Practitioner

Michal F Segal

Faculty

Michal F Segal

BSN, RN, OCN

Memorial Sloan Kettering Cancer Center, New York, New York

Clinical Trials Nurse II

Manish A Shah

Faculty

Manish A Shah

MD

Weill Cornell Medicine NewYork-Presbyterian Hospital, New York, New York

Professor of Medicine, Bartlett Family Professor of Gastrointestinal Oncology, Chief, Solid Tumor Oncology

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastroesophageal cancers.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with gastroesophageal cancers.

LEARNING OBJECTIVES

  • Understand validated biomarkers of response (eg, micro-satellite instability (MSI]/mismatch repair [MMR] deficiency, HER2 overexpression, PD-L1 combined positive score, CLDN18.2 expression) found in patients with gastric, gastroesophageal junction (GEJ) and esophageal cancers, and consider the implications for molecular testing and clinical care.
  • Appreciate the influence of various clinical and biological factors, such as histology, age, performance status and MSI/MMR status, on the use of neoadjuvant and adjuvant systemic therapy for patients with resectable gastric, GEJ and esophageal cancers.
  • Describe published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for metastatic gastric, GEJ and esophageal cancer in order to counsel patients regarding appropriate nonresearch treatment approaches.
  • Assess available data with monoclonal antibodies directed at CLDN18.2 in combination with chemotherapy as first-line treatment for CLDN18.2-positive gastric or GEJ cancer, and educate eligible patients about this novel strategy.
  • Understand how available HER2-targeted agents can be optimally incorporated into the management of HER2-positive metastatic gastroesophageal cancers.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
NCPD credit is no longer available for this issue.

ONCC/ILNA CERTIFICATION INFORMATION
NCPD credit is no longer available for this issue.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
NCPD credit is no longer available for this issue.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess financial relationships with faculty, planners and managers of NCPD activities. Financial relationships are identified and resolved through a financial relationship resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Sunnie Kim, MD
GI Medical Oncologist
Associate Professor
University of Colorado Cancer Center
Aurora, Colorado

Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Gilead Sciences Inc, I-Mab Biopharma, Merck; Contracted Research: Merck; Data and Safety Monitoring Boards/Committees: Jazz Pharmaceuticals Inc.

Brooke Parker, MSN, FNP
Gastrointestinal Oncology Nurse Practitioner
UCHealth Cancer Care
Aurora, Colorado

No relevant financial relationships to disclose.

Michal F Segal, BSN, RN, OCN
Clinical Trials Nurse II
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements: Astellas.

Manish A Shah, MD
Professor of Medicine
Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Oncology
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York

No relevant financial relationships to disclose.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Astellas and BeiGene Ltd.

Release date: May 2025
Expiration date: May 2026

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Shah

Module 1: Management of Localized or Locally Advanced Gastroesophageal Cancers; Current and Future Role of Immune Checkpoint Inhibitors

Al-Batran S-E et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet 2019;393(10184):1948-57. Abstract

Al-Batran S-E et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016;17(12):1697-708. Abstract

Janjigian YY et al. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. ESMO 2023;Abstract LBA73.

Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384(13):1191-203. Abstract

 

Module 3: Role of Therapy Targeting CLDN18.2 in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Baek JH et al. Clinical implications of Claudin18.2 expression in patients with gastric cancer. Anticancer Res 2019;39(12):6973-9. Abstract

Klempner SJ et al. Consensus guidance for management of nausea/vomiting in patients treated with zolbetuximab + chemotherapy: A RAND/UCLA modified Delphi panel study. ESMO Gastrointestinal Cancers Congress 2025;Abstract 506P.

Kuwata T. Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma. Pathol Int 2024;74(6):301-16. Abstract

Shitara K et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N Engl J Med 2024;391(12):1159-62. Abstract

 

Dr Kim

Module 2: Incorporation of Immunotherapeutic Strategies for HER2-Negative Metastatic Gastroesophageal Tumors

Chao J et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 2021;7(6):895-902. Abstract

Epistola R et al. Role of PD-1 inhibitors in the treatment of esophagogastric adenocarcinoma: Patient selection and reported outcomes. Cancer Manag Res 2023:15:265-75. Abstract

Janjigian YY et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649. Gastrointestinal Cancers Symposium 2025;Abstract 398.

Rha SY et al. KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations. ASCO 2023;Abstract 4014.

Ryu MH et al. KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer. ESMO Asia Congress 2024;Abstract 178P.

Shitara K et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022;603(7903):942-8. Abstract

 

Module 4: Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers

Janjigian YY et al. Pembrolizumab in HER2-positive gastric cancer. N Engl J Med 2024;391(14):1360-2. Abstract

Janjigian YY et al. Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03). ESMO 2024;Abstract 1401O.

Shitara K et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382(25):2419-30. Abstract

Shitara K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01). ASCO 2020;Abstract 4513.

Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). Gastrointestinal Cancers Symposium 2022;Abstract 242.

 

Ms Segal

Module 1: Management of Localized or Locally Advanced Gastroesophageal Cancers; Current and Future Role of Immune Checkpoint Inhibitors

Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349(23):2241-52. Abstract

 

Module 3: Role of Therapy Targeting CLDN18.2 in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Hesketh PJ et al. Antiemetics: ASCO guideline update. J Clin Oncol 2020;38(24):2782-97. Abstract

Nakayama I et al. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol 2024;21(5):354-69. Abstract

 

Ms Parker

Module 2: Incorporation of Immunotherapeutic Strategies for HER2-Negative Metastatic Gastroesophageal Tumors

Martins F et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16(9):563-80. Abstract

 

Module 4: Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers

Chiu Y-H et al. Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases: A cohort study. Front Med (Lausanne) 2023;10:1106560. Abstract

Shitara K et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382(25):2419-30. Abstract

  • for-nurses

Understanding the Current Paradigm and New Approaches in the Care of Patients with Non-Hodgkin Lymphoma

Accreditation types: 1.75 NCPD

Expired: May 2026

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Christopher Flowers

Faculty

Christopher Flowers

MD, MS

The University of Texas MD Anderson Cancer Center, Houston, Texas

Division Head, Division of Cancer Medicine, Chair, Professor, Department of Lymphoma/Myeloma, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine

Manali Kamdar

Faculty

Manali Kamdar

MD, MBBS

University of Colorado Cancer Center, Aurora, Colorado

Associate Professor, Clinical Director of Lymphoma Services, Morton and Sandra Saffer Endowed Chair in Hematology Research, Division of Hematology, Hematologic Malignancies

Robin Klebig

Faculty

Robin Klebig

MSN, APRN, CNP, AOCNP

Mayo Clinic, Rochester, Minnesota

Hematology Outpatient APP Supervisor, Assistant Professor of Medicine, Nurse Practitioner, Lymphoma Group, Division of Hematology

Caitlin Murphy

Faculty

Caitlin Murphy

DNP, FNP-BC, AOCNP

Dana-Farber Cancer Institute, Boston, Massachusetts

Clinical Nurse Practitioner, Director of Advanced Practice Nursing

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with non-Hodgkin lymphoma.

LEARNING OBJECTIVES

  • Identify patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy as a component of first-line treatment would be appropriate.
  • Understand published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents in treatment for DLBCL and follicular lymphoma (FL), and employ this information in patient education discussions.
  • Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates in therapy for patients with relapsed/refractory (R/R) DLBCL.
  • Evaluate published clinical research findings establishing the efficacy and safety of Bruton tyrosine kinase (BTK) inhibitors as a component of first-line therapy for mantle cell lymphoma (MCL), and assess the current and potential role of various BTK inhibitor-based strategies in the care of patients newly diagnosed with the disease.
  • Appreciate the biological rationale for, available data with and current clinical role of BTK inhibitors in treatment for patients with R/R MCL, and discern how these agents can be appropriately and safely integrated into routine practice.
  • Review published clinical research findings establishing the efficacy and safety of combined BTK inhibitor/anti-CD20 antibody therapy for R/R FL, and identify patients for whom treatment with available combinations would be appropriate.
  • Recognize the spectrum, frequency and severity of adverse events associated with various therapies commonly employed in the care of patients with NHL, and consider recommended approaches to prevent, ameliorate and manage resultant side effects.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
NCPD credit is no longer available for this issue.

ONCC/ILNA CERTIFICATION INFORMATION
NCPD credit is no longer available for this issue.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
NCPD credit is no longer available for this issue.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Christopher Flowers, MD, MS
Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.

Manali Kamdar, MD, MBBS
Associate Professor
Clinical Director of Lymphoma Services
Morton and Sandra Saffer Endowed Chair in Hematology Research
Division of Hematology, Hematologic Malignancies
University of Colorado Cancer Center
Aurora, Colorado

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group; Contracted Research: Novartis; Data and Safety Monitoring Board/Committees: Celgene Corporation, Genentech, a member of the Roche Group.

Robin Klebig, MSN, APRN, CNP, AOCNP
Hematology Outpatient APP Supervisor
Assistant Professor of Medicine
Nurse Practitioner, Lymphoma Group
Division of Hematology
Mayo Clinic
Rochester, Minnesota

No relevant financial relationships to disclose.

Caitlin Murphy, DNP, FNP-BC, AOCNP
Clinical Nurse Practitioner
Director of Advanced Practice Nursing
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committees: Genmab US Inc, Seagen Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from ADC Therapeutics and AstraZeneca Pharmaceuticals LP.

Release date: May 2025
Expiration date: May 2026

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Kamdar

Module 1: Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma

Dreyling M et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 2024;403(10441):2293-306. Abstract

Dreyling M et al. Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: Results from the randomized Triangle trial by the European MCL Network. ASH 2024;Abstract 240.

Jain P et al. Acalabrutinib with rituximab is highly effective first line treatment for older patients with mantle cell lymphoma. ASH 2024;Abstract 3038.

Kumar A et al. A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma. ASH 2023;Abstract 738.

Wang M et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA 2024;Abstract LBA3439.

Wang M et al. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Adv 2024;8(17):4539-48. Abstract

Wang M et al. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): A single-arm, phase 2 trial. Lancet Oncol 2022;23(3):406-15. Abstract

 

Module 3: Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL

Caimi PF et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica 2024;109(4):1184-93. Abstract

Epperla N et al. Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood Cancer J 2024;14(1):210. Abstract

Hamadani M et al. Real‐world treatment of large B‐cell lymphoma with chimeric antigen receptor T‐cell therapy after loncastuximab tesirine. EJHaem 2024;5(5):1110–3. Abstract

 

Dr Flowers

Module 2: First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) 

Palmer AC et al. Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin. N Engl J Med 2023;389(8):764-6. Abstract

Peyrade F et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12(5):460-8. Abstract

Salles G et al. Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. ASH 2024;Abstract 469.

Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract

Teras LR et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66(6):443-59. Abstract

Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract

 

Module 4: Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma

Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract

Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica 2024;109(2):553-66. Abstract

Duell J et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021;106(9):2417-26. Abstract

Kalakonda N et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7(7):e511-22. Abstract

Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21(7):978-88. Abstract

Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA-1.

Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv 2022;6(2):533-43. Abstract

Vercellino L et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2020;4(22):5607-15. Abstract

  • for-nurses

Understanding the Current Paradigm and New Approaches in the Care of Patients with Ovarian Cancer

Accreditation types: 1.75 NCPD

Expired: April 2026

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Courtney Arn

Faculty

Courtney Arn

CNP

The Ohio State University, Columbus, Ohio

The James Cancer Hospital and Solove Research Institute

Jennifer Filipi

Faculty

Jennifer Filipi

MSN, NP

Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Department of Gynecologic Oncology

David M O'Malley

Faculty

David M O'Malley

MD

The Ohio State University and The James Comprehensive Cancer Center, Columbus, Ohio

Director and Professor, Division of Gynecologic Oncology in Obstetrics and Gynecology, John G Boutselis Chair in Gynecologic Oncology

Shannon N Westin

Faculty

Shannon N Westin

MD, MPH, FASCO, FACOG

The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Medical Director, Gynecologic Oncology Center, Director, Early Drug Development, Department of Gynecologic Oncology and Reproductive Medicine

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with cancer.

LEARNING OBJECTIVES

  • Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC, and counsel appropriate individuals regarding personalized treatment recommendations.
  • Assess available clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to optimally and appropriately incorporate these agents into current management algorithms.
  • Evaluate the biological rationale for and published clinical research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings.
  • Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
  • Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for this newly relevant biomarker.
  • Understand the structural components and mechanism of action of antibody-drug conjugates directed at folate receptor alpha, and discuss current research findings with these agents.
  • Appreciate the side effects associated with various systemic therapies commonly employed for OC, and use this information to develop supportive management plans for patients.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of April 2025 to April 2026.

This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/OvarianCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/Ovarian/Video/NCPD.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Courtney Arn, CNP
The James Cancer Hospital and Solove Research Institute
The Ohio State University
Columbus, Ohio

Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, ImmunoGen Inc, Merck, Pfizer Inc.

Jennifer Filipi, MSN, NP
Department of Gynecologic Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

No relevant conflicts of interest to disclose.

David M O’Malley, MD
Director and Professor
Division of Gynecologic Oncology in Obstetrics and Gynecology
John G Boutselis Chair in Gynecologic Oncology
The Ohio State University and The James Comprehensive Cancer Center
Columbus, Ohio

Advisory Committees and Consulting Agreements (Personal Fees): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, Eisai Inc, GSK, ImmunoGen Inc, Merck, MSD, Novocure Inc, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds for Research): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Data and Safety Monitoring Board/Committees: Frantz Viral Therapeutics; Nonrelevant Financial Relationships: GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG Foundation, SWOG.

Shannon N Westin, MD, MPH, FASCO, FACOG
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo Inc, Eisai Inc, EQRx, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Seagen Inc, Verastem Inc, Vincerx Pharma, Zentalis Pharmaceuticals, ZielBio; Contracted Research (to Institution): AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Clovis Oncology, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Zentalis Pharmaceuticals.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Merck.

Release date: April 2025
Expiration date: April 2026

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Westin

Module 1: Genetic Testing for Newly Diagnosed Advanced OC

Burger RA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83. Abstract

Konstantinopoulos PA et al. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015;5(11):1137-54. Abstract

Lin J et al. Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. Gynecol Oncol 2021;162(2):506-16. Abstract

Perren TJ et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96. Abstract

Module 4: Current and Future Role of Mirvetuximab Soravtansine in OC Treatment

Alvarez Secord A et al. The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: The single-arm phase II PICCOLO trial. Ann Oncol 2025;36(3):321-30. Abstract

Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. J Clin Oncol 2023;41(13):2436-45. Abstract

Moore KN et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;389(23):2162-74. Abstract

Moore KN et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase I expansion study. J Clin Oncol 2017;35(10):1112-8. Abstract

 

Dr O’Malley

Module 2: Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC

DiSilvestro P et al. Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial. ESMO 2022;Abstract 5170.

González‑Martín A et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):2391-402. Abstract

Monk BJ et al. ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC). ESMO 2024;Abstract LBA30.

Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505. Abstract

Ray-Coquard IL et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). ESMO 2022;Abstract LBA29.

Ray-Coquard IL et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. ESMO 2019;Abstract LBA2_PR.

Sonnenblick A et al. An update on PARP inhibitors–moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12(1):27-41. Abstract

Trillsch F et al. Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O. ESMO Gynaecological Cancers Congress 2024;Abstract 43O.

Vergote I et al. Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA non-mutated epithelial ovarian cancer: Results from the randomized phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 study. ESGO 2025;Abstract 128.

Module 3: Other Available and Investigational Novel Strategies for OC

Lee J-Y et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2- expressing solid tumors: Results from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study. IGCS 2023;Abstract 1550.

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Moore KN et al. Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study. ESMO 2023;Abstract 745MO.

Uzunparmak B et al. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 2023;34(11):1035-46. Abstract

 

Ms Arn

Module 3

Powell CA et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 2022;7(4):100554. Abstract

Rugo HS et al. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open 2022;7(4):100553. Abstract

Swain SM et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022;106:102378. Abstract

Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: The five “S” rules. JCO Oncol Pract 2023;19(8):526-7. Abstract

  • for-nurses

Understanding the Current Paradigm and New Approaches: The Optimal Implementation of Antibody-Drug Conjugates in the Care of Patients with Cancer

Accreditation types: 1.75 NCPD

Expired: April 2026

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Marianne J Davies

Faculty

Marianne J Davies

DNP, ACNP, AOCNP, FAAN

Yale New Haven Health, New Haven, Connecticut

Program Manager, Care Signature, Oncology Service Line

Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut

Oncology Nurse Practitioner-Senior APP II

Yale University School of Nursing, New Haven, Connecticut

Associate Professor

Edward B Garon

Faculty

Edward B Garon

MD, MS

David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Los Angeles, California

Professor, Director, Thoracic Oncology Program, Director, Signal Transduction and Therapeutics Research Program

Marissa Marti-Smith

Faculty

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Tiffany A Traina

Faculty

Tiffany A Traina

MD, FASCO

Memorial Sloan Kettering Cancer Center, New York, New York

Vice Chair, Department of Medicine, Section Head, Triple-Negative Breast Cancer Clinical Research Program, Associate Attending Physician, Breast Medicine Service

Weill Cornell Medical College, New York, New York

Associate Professor

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with cancer.

LEARNING OBJECTIVES

  • Consider the scientific justification for the use of antibody-drug conjugates (ADCs) as a therapeutic approach for patients with various tumor types, and recall the targets, structural components and mechanisms of activity of different clinically available and investigational agents in this class.
  • Appraise available clinical research data with novel ADCs for various cancers, and consider the current and potential role of these approaches in routine clinical care.
  • Appreciate the pathophysiology and severity of common and rare toxicities associated with ADCs employed in the treatment of different tumor types.
  • Understand the incidence of toxicities observed in pivotal trials evaluating novel ADCs, and educate patients about to commence therapy with these approaches regarding the potential development of these adverse events and what to do if they are suspected.
  • Recall strategies commonly employed to identify, manage and mitigate resultant toxicities of anticancer treatment with ADCs, and use this information to appropriately intervene for patients in whom these side effects are suspected or diagnosed.
  • Understand the role of multidisciplinary specialists such as cardiologists, ophthalmologists and other medical professionals in the diagnosis and management of ADC-associated toxicities, and effectively educate patients regarding the potential need for and importance of specialty referral.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of April 2025 to April 2026.

This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/ADCs/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/ADCsPanTumor/Video/NCPD.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Marianne J Davies, DNP, ACNP, AOCNP, FAAN
Program Manager, Care Signature
Oncology Service Line, Yale New Haven Health
Oncology Nurse Practitioner-Senior APP II
Yale Cancer Center
Smilow Cancer Hospital at Yale New Haven
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

No relevant conflicts of interest to disclose.

Edward B Garon, MD, MS
Professor
Director, Thoracic Oncology Program
Director, Signal Transduction and Therapeutics Research Program
David Geffen School of Medicine at UCLA
Jonsson Comprehensive Cancer Center
Los Angeles, California

Advisory Committees and Consulting Agreements: AbbVie Inc, Arcus Biosciences, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Atreca, Black Diamond Therapeutics Inc, BridgeBio, Bristol Myers Squibb, EMD Serono Inc, Gilead Sciences Inc, Hookipa Pharma Inc, I-Mab Biopharma, LianBio, Lilly, Merck, Merus, Novartis, Nuvalent, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Sensei Biotherapeutics, Strata Oncology, Sumitomo Dainippon Pharma Oncology Inc, Summit Therapeutics, Synthekine; Contracted Research: ABL Bio, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics Inc, Novartis, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Synthekine, TILT Biotherapeutics; Sponsored Independent Medical Education: Daiichi Sankyo Inc; Travel: A2 Bio, Novartis.

Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology-Baylor Charles A Sammons Cancer Center
Dallas, Texas

Speakers Bureaus: Biotheranostics Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Advantage, Clinical Education Alliance.

Tiffany A Traina, MD, FASCO
Vice Chair, Department of Medicine
Section Head, Triple-Negative Breast Cancer Clinical Research Program
Associate Attending Physician
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Associate Professor
Weill Cornell Medical College
New York, New York

Advisory Committees and Consulting Agreements: Aktis Oncology, AstraZeneca Pharmaceuticals LP, BioNTech SE, Daiichi Sankyo Inc, Ellipses Pharma, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Merck, Pfizer Inc, Stemline Therapeutics Inc, TerSera Therapeutics LLC, Veracyte Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

Release date: April 2025
Expiration date: April 2026

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Traina

Module 2: Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases

André F et al. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Ann Oncol 2024;35(12):1169-80. Abstract

Cortés J et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial. Nat Med 2024;30(8):2208-15. Abstract

Curigliano G et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol 2022;33(3):321-9. Abstract

Hamilton EP et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. ASCO 2024;Abstract 1025.

Harbeck N et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: A phase 3b/4 trial. Nat Med 2024;30(12):3717-27. Abstract

Hurvitz SA et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. ESMO 2023;Abstract 377O.

Murthy RK et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020;382(7):597-609. Abstract

Saura C et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol 2024;35(3):302-7. Abstract

Swain SM et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020;21(4):519-30. Abstract

 

Module 3: Role of ADCs for Patients with ER-Positive mBC

Bardia A et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 2024;391(22):2110-22. Abstract

Bardia A et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. ESMO 2023;Abstract LBA11.

Bardia A et al. Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01. San Antonio Breast Cancer Symposium 2023;Abstract GS02-01.

Curigliano G et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). ASCO 2024;Abstract LBA1000.

Huppert LA et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies. ASCO 2024;Abstract 1083.

Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. ESMO 2023;Abstract 376O.

Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet 2023;402(10411):1423-33. Abstract

Rugo HS et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. ASCO 2022;Abstract LBA1001.

Tolaney SM et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). ASCO 2023;Abstract 1003.

 

Ms Marti-Smith

Module 2: Overview of Antibody-Drug Conjugates (ADCs)

Rugo HS et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol Pract 2023;19(8):539-46. Abstract

 

Module 3: Role of ADCs for Patients with ER-Positive mBC

Spring LM et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: Clinical overview and management of potential toxicities. Oncologist 2021;26(10):827-34. Abstract

 

Dr Garon

Module 4: T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations

Goto K et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol 2023;41(31):4852-63. Abstract

Janne PA et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. ASCO 2024;Abstract 8543.

Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract

Odintsov I et al. Prevalence and therapeutic targeting of high-level ERBB2 amplification in NSCLC. J Thorac Oncol 2024;19(5):732-48. Abstract

Planchard D et al. Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-Lung03 part 1. WCLC 2024;Abstract OA16.05.

Uzunparmak B et al. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 2023;34(11):1035-46. Abstract

Waliany S et al. Real-world prevalence, treatment patterns, and outcomes for patients with HER2 (ERBB2)-mutant metastatic non-small cell lung cancer, from a US-based clinico-genomic database. Cancer Med 2024;13(24):e70272. Abstract

 

Module 5: Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC

Ahn M et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. ESMO 2023;Abstract LBA12.

Krop IE et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). ASCO 2022;Abstract 1002.

Paz-Ares L et al. TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). ESMO 2023;Abstract 1314MO.

Sands J et al. Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01. WCLC 2024;Abstract OA08.03.

Yu HA et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol 2023;41(35):5363-75. Abstract

 

Ms Davies

Module 4: T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations

Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: The five “S” rules. JCO Oncol Pract 2023;19(8):526-7. Abstract

Tarantino P et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: A review. JAMA Oncol 2021;7(12):1873-81. Abstract

 

Module 5: Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC

Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract

  • for-nurses
  • NCPD